BioXcel Therapeutics, Inc. IPO Research Information

BioXcel Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on BioXcel Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
BioXcel Therapeutics, Inc.	BTAI - NASDAQ	$11.00-$13.00	$11.00	$11.02	5.4 million	3/8/2018
Underwriter(s): Barclays, UBS Investment Bank, BMO Capital Markets
Co-Manager(s): Canaccord Genuity
Industry: Health Care
Filing(s): Final Prospectus 2018-03-09 Filed 2018-02-12 Terms Added 2018-02-27

BioXcel Therapeutics, Inc. Quote & Chart - Click for current quote - BTAI

About BioXcel Therapeutics, Inc. (adapted from BioXcel Therapeutics, Inc. prospectus):
They are a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "BTAI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.